Post-induction residual disease in translocation t(12;21)-positive childhood ALL

Jeanette Seyfarth; Hans O Madsen; Charlotte Nyvold; Lars P Ryder; Niels Clausen; Gudmundur K Jonmundsson; Finn Wesenberg; Kjeld Schmiegelow

doi:10.1002/mpo.10217

Post-induction residual disease in translocation t(12;21)-positive childhood ALL

Jeanette Seyfarth, Hans O Madsen, Charlotte Nyvold, Lars P Ryder, Niels Clausen, Gudmundur K Jonmundsson, Finn Wesenberg, Kjeld Schmiegelow

Department of Paediatrics and Adolescent Medicine

4 Citations (Scopus)

Abstract

BACKGROUND: t(12;21)(p1 3;q22), the most frequent chromosomal translocation found in childhood acute lymphoblastic leukemia (ALL), occurs in approximately 25% of B-lineage ALL cases and has been claimed to carry a good prognosis.

PROCEDURE: As part of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL-MRD 95 study, which includes children from Iceland, Norway, and Denmark diagnose d with ALL, patients were screened for the presence of t(12; 21) by reverse transcriptase-polymerase chain reaction (RT-PCR) at diagnosis, and their residual disease was quantified after 4 weeks of induction therapy (prednisolone, vincristine, doxorubicin, i.t. methotrexate) by a competitive, clone-specific, semi-nested PCR analysis.

RESULTS: Among 96 children diagnosed with ALL, and quantified for post induction residual disease, 32 were t(12;21)-positive. The median residual disease was similar for B-precursor ALL patients with and without t(12;21) (0.009 vs. 0.03%, P = 0.12).

CONCLUSIONS: Al though patients with t(12;21)-positive ALL have been claimed to have a good outcome, these data indicate that this does not reflect a high sensitivity to prednisolone, vincristine, and doxorubicin given during induction therapy.

Original language	English
Journal	Medical and Pediatric Oncology
Volume	40
Issue number	2
Pages (from-to)	82-7
Number of pages	6
ISSN	0098-1532
DOIs	https://doi.org/10.1002/mpo.10217
Publication status	Published - Feb 2003

Keywords

Adolescent
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Child
Child, Preschool
Chromosomes, Human, Pair 12/genetics
Chromosomes, Human, Pair 21/genetics
Core Binding Factor Alpha 2 Subunit
DNA Primers/chemistry
Doxorubicin/administration & dosage
Female
Humans
Immunophenotyping
Infant
Male
Methotrexate/administration & dosage
Neoplasm, Residual/drug therapy
Oncogene Proteins, Fusion/genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
Prednisolone/administration & dosage
RNA, Messenger/metabolism
RNA, Neoplasm/metabolism
Remission Induction
Reverse Transcriptase Polymerase Chain Reaction
Translocation, Genetic
Vincristine/administration & dosage

Access to Document

10.1002/mpo.10217

Cite this

@article{65d3da1c2cd54be0ab54301c68583c1f,

title = "Post-induction residual disease in translocation t(12;21)-positive childhood ALL",

abstract = "BACKGROUND: t(12;21)(p1 3;q22), the most frequent chromosomal translocation found in childhood acute lymphoblastic leukemia (ALL), occurs in approximately 25\% of B-lineage ALL cases and has been claimed to carry a good prognosis.PROCEDURE: As part of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL-MRD 95 study, which includes children from Iceland, Norway, and Denmark diagnose d with ALL, patients were screened for the presence of t(12; 21) by reverse transcriptase-polymerase chain reaction (RT-PCR) at diagnosis, and their residual disease was quantified after 4 weeks of induction therapy (prednisolone, vincristine, doxorubicin, i.t. methotrexate) by a competitive, clone-specific, semi-nested PCR analysis.RESULTS: Among 96 children diagnosed with ALL, and quantified for post induction residual disease, 32 were t(12;21)-positive. The median residual disease was similar for B-precursor ALL patients with and without t(12;21) (0.009 vs. 0.03\%, P = 0.12).CONCLUSIONS: Al though patients with t(12;21)-positive ALL have been claimed to have a good outcome, these data indicate that this does not reflect a high sensitivity to prednisolone, vincristine, and doxorubicin given during induction therapy.",

keywords = "Adolescent, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Child, Child, Preschool, Chromosomes, Human, Pair 12/genetics, Chromosomes, Human, Pair 21/genetics, Core Binding Factor Alpha 2 Subunit, DNA Primers/chemistry, Doxorubicin/administration \& dosage, Female, Humans, Immunophenotyping, Infant, Male, Methotrexate/administration \& dosage, Neoplasm, Residual/drug therapy, Oncogene Proteins, Fusion/genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy, Prednisolone/administration \& dosage, RNA, Messenger/metabolism, RNA, Neoplasm/metabolism, Remission Induction, Reverse Transcriptase Polymerase Chain Reaction, Translocation, Genetic, Vincristine/administration \& dosage",

author = "Jeanette Seyfarth and Madsen, \{Hans O\} and Charlotte Nyvold and Ryder, \{Lars P\} and Niels Clausen and Jonmundsson, \{Gudmundur K\} and Finn Wesenberg and Kjeld Schmiegelow",

year = "2003",

month = feb,

doi = "10.1002/mpo.10217",

language = "English",

volume = "40",

pages = "82--7",

journal = "Medical and Pediatric Oncology",

issn = "0098-1532",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Post-induction residual disease in translocation t(12;21)-positive childhood ALL

AU - Seyfarth, Jeanette

AU - Madsen, Hans O

AU - Nyvold, Charlotte

AU - Ryder, Lars P

AU - Clausen, Niels

AU - Jonmundsson, Gudmundur K

AU - Wesenberg, Finn

AU - Schmiegelow, Kjeld

PY - 2003/2

Y1 - 2003/2

N2 - BACKGROUND: t(12;21)(p1 3;q22), the most frequent chromosomal translocation found in childhood acute lymphoblastic leukemia (ALL), occurs in approximately 25% of B-lineage ALL cases and has been claimed to carry a good prognosis.PROCEDURE: As part of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL-MRD 95 study, which includes children from Iceland, Norway, and Denmark diagnose d with ALL, patients were screened for the presence of t(12; 21) by reverse transcriptase-polymerase chain reaction (RT-PCR) at diagnosis, and their residual disease was quantified after 4 weeks of induction therapy (prednisolone, vincristine, doxorubicin, i.t. methotrexate) by a competitive, clone-specific, semi-nested PCR analysis.RESULTS: Among 96 children diagnosed with ALL, and quantified for post induction residual disease, 32 were t(12;21)-positive. The median residual disease was similar for B-precursor ALL patients with and without t(12;21) (0.009 vs. 0.03%, P = 0.12).CONCLUSIONS: Al though patients with t(12;21)-positive ALL have been claimed to have a good outcome, these data indicate that this does not reflect a high sensitivity to prednisolone, vincristine, and doxorubicin given during induction therapy.

AB - BACKGROUND: t(12;21)(p1 3;q22), the most frequent chromosomal translocation found in childhood acute lymphoblastic leukemia (ALL), occurs in approximately 25% of B-lineage ALL cases and has been claimed to carry a good prognosis.PROCEDURE: As part of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL-MRD 95 study, which includes children from Iceland, Norway, and Denmark diagnose d with ALL, patients were screened for the presence of t(12; 21) by reverse transcriptase-polymerase chain reaction (RT-PCR) at diagnosis, and their residual disease was quantified after 4 weeks of induction therapy (prednisolone, vincristine, doxorubicin, i.t. methotrexate) by a competitive, clone-specific, semi-nested PCR analysis.RESULTS: Among 96 children diagnosed with ALL, and quantified for post induction residual disease, 32 were t(12;21)-positive. The median residual disease was similar for B-precursor ALL patients with and without t(12;21) (0.009 vs. 0.03%, P = 0.12).CONCLUSIONS: Al though patients with t(12;21)-positive ALL have been claimed to have a good outcome, these data indicate that this does not reflect a high sensitivity to prednisolone, vincristine, and doxorubicin given during induction therapy.

KW - Adolescent

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Child

KW - Child, Preschool

KW - Chromosomes, Human, Pair 12/genetics

KW - Chromosomes, Human, Pair 21/genetics

KW - Core Binding Factor Alpha 2 Subunit

KW - DNA Primers/chemistry

KW - Doxorubicin/administration & dosage

KW - Female

KW - Humans

KW - Immunophenotyping

KW - Infant

KW - Male

KW - Methotrexate/administration & dosage

KW - Neoplasm, Residual/drug therapy

KW - Oncogene Proteins, Fusion/genetics

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy

KW - Prednisolone/administration & dosage

KW - RNA, Messenger/metabolism

KW - RNA, Neoplasm/metabolism

KW - Remission Induction

KW - Reverse Transcriptase Polymerase Chain Reaction

KW - Translocation, Genetic

KW - Vincristine/administration & dosage

UR - https://www.scopus.com/pages/publications/0037290952

U2 - 10.1002/mpo.10217

DO - 10.1002/mpo.10217

M3 - Journal article

C2 - 12461790

SN - 0098-1532

VL - 40

SP - 82

EP - 87

JO - Medical and Pediatric Oncology

JF - Medical and Pediatric Oncology

IS - 2

ER -

Post-induction residual disease in translocation t(12;21)-positive childhood ALL

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this